Investor presentation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Syschem India has shared its investor deck covering Q1 FY26 (Jun-25). The company manufactures bulk drugs/intermediates and offers contract manufacturing from its ISO and cGMP-certified facility in Kalka, Haryana. Key financials show a 24% year-on-year revenue growth in Jun-25 versus Jun-24, though there was a modest quarter-on-quarter dip versus Mar-25 attributed to early-year demand weakness. Production volumes rose sharply — 95% by Mar-25 and 81% by Jun-25 compared to Jun-24 — while EBITDA improved and PBT reached ₹167.4 lakhs, with EPS rising to ₹0.38. The roadmap highlights an under-construction new manufacturing unit for cloxacillin, dicloxacillin, and flucloxacillin with WHO-GMP compliance to boost capacity. The company exports to Latin America, Africa, Thailand, Sri Lanka, Nepal, Indonesia, Germany, Bangladesh, and MENA, operating across 12 Indian states and 7+ international markets.
Positive for shareholders — the deck confirms margin improvement, capacity expansion plans, and export-led growth visibility, though the QoQ revenue dip may temper near-term sentiment. Investors should watch execution of the new antibiotic API unit and sustained demand recovery beyond early FY26.